Skip to content

iBio’s Drug Discovery Platform2 aims to increase the likelihood of success. Using artificial intelligence (AI), our platform efficiently and consistently delivers antibody candidates against difficult targets.

At the heart of the platform is our patented epitope-engineering technology, which we use to engineer mini-proteins embodying the structure of conformational epitopes, including subdominant epitopes, to discover traditionally challenging therapeutic antibodies. An epitope is the region of a target protein to which antibodies bind. The range of potential epitopes or binding sites on a target is enormous. But not all epitopes are created equally.

Traditional drug discovery has allowed the immune system to drive epitope selection and thus biasing antibody selection towards immunodominant epitopes rather than subdominant epitopes. Often, the most efficacious epitopes are not immunodominant epitopes, but rather subdominant epitopes and therefore without epitope steering the best therapeutic antibodies are missed using traditional drug discovery methods.

By combining our Epitope-Engineering technology with a proprietary human Antibody Library, our StableHu™ Antibody Optimizer, and EngageTx™ for engineering bispecifics, iBio can potentially increase the probability of success for hard-to-drug targets and move them into the clinic faster.

Overview of iBio’s Discovery platform

Linear diagram with 6 steps. Step 1. Epitope Engineering Engine: AI-powered precision targeting conformational & subdominant epitopes. Step 2. Engineered epitope: Epitope-specific antigens built to efficiently and selectively discover antibodies. Step 3: AI-generative naïve antibody library, free of sequence liabilities. Step 4: AI-powered sequence optimization to improve performance. Step 5: Optimized bi-specifics leveraging broad potency range, human-monkey cross-reactivity, & sequence diversity. Step 6: Optimized leads evaluated & ranked in translational disease models. Final: On-Epitope Clinical Candidate

iBio’s Antibody Discovery Platform In Action

Epitope-Steered Antibodies for Precision Immunotherapies

  1. Devol, Ross & Bedroussian, Armen & Yeo, Benjamin. (2022). The Global Biomedical Industry: Preserving U.S. Leadership.
  2. U.S. Patent No. 11,545,238 (issued January 3, 2023)